A Prospective, Single-center, Open-label Phase II Clinical Study of Intra-arterial Chemotherapy Combined with Concurrent Radiotherapy and Tislelizumab-jsgr in the Treatment of T4bNanyM0 HNSCC
Latest Information Update: 13 Dec 2024
Price :
$35 *
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel (Primary) ; Tislelizumab (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 13 Dec 2024 New trial record